Cardiovascular toxicity in breast cancer patients – contributors and role of cardioprotective drugs
Submitted: December 30, 2022
Accepted: January 30, 2023
Published: March 28, 2023
Accepted: January 30, 2023
Abstract Views: 1206
PDF: 282
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Miguel Osejo-Betancourt, Sebastian Molina-Paez , Mariana Rubio-Romero , Pulmonary tuberculosis and COVID-19 coinfection: A new medical challenge , Monaldi Archives for Chest Disease: Vol. 92 No. 3 (2022)
- Rita Intravaia, Benedetta De Chiara, Francesco Musca, Francesca Casadei, Gloria Santambrogio, Francesca Spanò, Oriana Belli, Giuseppina Quattrocchi, Cristina Giannattasio, Antonella Moreo, Primary mediastinal large B-cell lymphoma and pregnancy: a challenging clinical scenario , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Danish Abdul Aziz, Muhammad Aqib Sajjad, Ameema Asad, Global Initiative for Asthma (GINA) guideline: achieving optimal asthma control in children aged 6-11 years , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Federico Raimondi, Stefano Centanni, Fabrizio Luppi, Stefano Aliberti, Francesco Blasi, Paola Rogliani, Claudio Micheletto, Marco Contoli, Alessandro Sanduzzi Zamparelli, Marialuisa Bocchino, Paolo Busatto, Luca Novelli, Simone Pappacena, Luca Malandrino, Giorgio Lorini, Greta Cairoli, Fabiano Di Marco, Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients , Monaldi Archives for Chest Disease: Early Access
You may also start an advanced similarity search for this article.